A. Soto Matos-Pita

Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study

Emiliano Calvo, Víctor Moreno, Michael Flynn et al. · Annals of Oncology · 2017 · 85 citations · Full text

Medicine, Oncology, Pharmacology +12

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study

B.J. Monk, Prafull Ghatage, Trilok Parekh et al. · Annals of Oncology · 2015 · 65 citations

Medicine, Oncology, Pharmacology +15

Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors

Ramón Salazar, H. Cortés-Funes, E. Casado et al. · Cancer Chemotherapy and Pharmacology · 2013 · 32 citations

Medicine, Oncology, Pharmacokinetics +12

First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors

Elena Élez, Carlos Gomez‐Roca, A. Soto Matos-Pita et al. · Investigational New Drugs · 2018 · 22 citations

Medicine, Oncology, Pharmacology +9

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule

Antonio Jimeno, Manish Sharma, Sergio Szyldergemajn et al. · Investigational New Drugs · 2017 · 20 citations

Life Sciences, Molecular Biology, Pharmacology +17